Technology
Health
Pharmaceutical
Evelo Biosciences
$7.509876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$7.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.36 (-4.58%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours
Why Robinhood?
You can buy or sell EVLO and other stocks, options, ETFs, and crypto commission-free!
About EVLO
Evelo Biosciences, Inc. operates as a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines. Its product candidates are single strains of microbes, selected for defined pharmacological properties. Read More The firm currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.
CEO
Employees
75
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
251.76M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
29.00K
High Today
$7.88
Low Today
$7.28
Open Price
$7.81
Volume
21.94K
52 Week High
$15.89
52 Week Low
$6.32
Collections
Technology
Health
Pharmaceutical
Medical
Biotechnology
Cancer Prevention
2018 IPO
US
Price Paid on Robinhood
33% Lower
Right Now
52 Week Low
$6.51
Average Price Paid
$11.17
52 Week High
$16.75
EVLO Earnings
-$3.29
-$2.31
-$1.34
-$0.36
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 1, Pre-Market